Methodologies for the study of ocular surface disease

Ocular Surface

Volumn 3, Issue 3, 2005, Pages 143-154

  Ousler, George W ^a,b   Gomes, Paulo J ^a,b   Welch, Donna ^a,b   Abelson, Mark B ^a,b  

^a SCHEPENS EYE RESEARCH INSTITUTE   (United States)

^b Ophthalmic Research Associates Inc   (United States)

Author keywords

Allergy; Challenge models; Clinicals trials; Conjunctivitis; Controlled adverse environment model; Controlled allergen challenge model; Dry eye disease; Keratoconjunctivitis; Ocular allergy

Indexed keywords

ANTIALLERGIC AGENT; ARTIFICIAL TEAR; ASTRINGENT AGENT; CYCLOSPORIN A; EMOLLIENT AGENT; EOSINOPHIL CATIONIC PROTEIN; HISTAMINE; LUBRICATING AGENT; OLOPATADINE; PLACEBO; SOOTHE; SYSTANE; THROMBOCYTE ACTIVATING FACTOR; TRYPTASE;

ALLERGIC CONJUNCTIVITIS; ALLERGIC DISEASE; ARTICLE; ATOPIC KERATOCONJUNCTIVITIS; CLINICAL TRIAL; CORNEA SENSIBILITY; DIAGNOSTIC ACCURACY; DISEASE MODEL; DRY EYE; ENVIRONMENTAL FACTOR; EYE DISEASE; FLUOROPHOTOMETRY; HUMAN; LIFESTYLE; METHODOLOGY; NONHUMAN; OSMOLARITY; PATHOGENESIS; SKIN TEST; STATISTICAL SIGNIFICANCE; VERNAL CONJUNCTIVITIS;

EID: 24644481919     PISSN: 15420124     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1542-0124(12)70196-9     Document Type: Article

References (66)

1. Abelson MB, Chapin MJ. Current and future topical treatments for ocular allergy. Comp Ophthalmol Update 2000;1:303-17
2. Abelson MB, Udel IJ, Weston JH. Conjunctival eosinophils in allergic ocular disease. Arch Ophthalmol 1983;101:631
3. Insler MS, Lim JM, Queng JT, et al. Tear and serum IgE concentrations by tandem-R IgE immunoradiometric assay in allergic patients. Ophthalmology 1987;94:945
4. Allansmith MR, Hann GS, Simon MA. Tissue tear and serum IgE concentrations in vernal conjunctivitis. Am J Ophthalmol 1976;81:506
5. Abelson MB, Soter NA, Simon MA, et al. Histamine in human tears. Am J Ophthalmol 1977;83:417-8
6. Abelson MB, Udell IJ. H2-receptors in the human ocular surface. Arch Ophthalmol 1981;99:302-4
7. Abelson MB, Madiwale NA, Weston JH. Conjunctival eosinophils in allergic ocular disease. Arch Ophthalmol 1983;101:555
8. Leonardi A. Vernal keratoconjunctivitis: pathogenesis and treatment. Prog Retin Eye Res 2002;21:319-39
9. Casey R. Atopic keratoconjunctivitis, in Abelson MB (ed). Allergic diseases of the eye. WB Saunders, Philadelphia, 2001, pp 137-43
10. Blackley CH. Experimental researchers on the cause and nature of catarrhus acativas, Chapter in Hay Fever or Hay Asthma. London, Bailliere, Tindal, Cox, Ltd, 1873
11. Noon L. Prophylactic inoculation against hay fever. Lancet 1911;1:1572
12. Peshkin MM. A dry pollen ophthalmic test in pollen asthma and hayfever patients negative to cutaneous tests. J Allergy 1931;3:20-9
13. Abram LE. An evaluation of conjunctival testing in extrinsic respiratory allergy. J Allergy 1949;20:66-9
14. Tuft L, Tornsey PJ, Ettelson LN, Heck VM. Ophthalmic and nasal, mucosal testing as an aid in the determination of house dust allergy. J Allergy 1962;33:448-57
15. Tuft L. The value of eye tests with inhalant allergens- a clinical study. Ann Allergy 1967;25:183-91
16. Stegman R, Miller D. A human model of allergic conjunctivitis. Arch Ophthalmol 1975;93:1354-8
17. Mikuni I. The use of provocation tests for the diagnosis of allergic conjunctivitis caused by Japanese cedar pollen. Tokai J Exp Clin Med 1980;5:375-84
18. Bacon AS, Ahluwalia P, Irani AM, et al. Tear and conjunctival changes during the allergen-induced early- and late-phase responses. J Allergy Clin Immunol 2000;106:948-54
19. Margrini L, Bonini S, Centotanti M, et al. Tear tryptase levels and allergic conjunctivitis. Allergy 1996; 51:577-81
20. Montan PG, van Hage-Hamsten M, Zetterstrom O. Sustained eosinophil cationic protein release into tears after a single high-dose conjunctival allergen challenge. Clin Exp Allergy 1996;26:1105-7
21. Leonardi AA, Abelson MB. Double-masked, randomized, placebo-controlled clinical study of the mast cell-stabilizing effects of treatment with olopatadine in the conjunctival allergen challenge model in humans. Clin Ther 2003;25:2539-52
22. Abelson MB, Turner D. A randomized, double-blind, parallel-group comparison of olopatadine 0.1% ophthalmic solution versus placebo for controlling the signs and symptoms of seasonal allergic conjunctivitis and rhinoconjunctivitis. Clin Ther 2003;25 931-47
23. White VW. The role of histamine in allergic diseases. J Allergy Clin Immunol 1990;86:599-605
24. Church MK, Holgate ST, Shute JK, et al. Mast cell-derived mediators, in Middleton E, Reed CE, Ellis ET, et al (eds). Allergy. Principles and Practice. Mosby, St Louis, 1998, pp 146-67
25. Abelson MB, Allansmith MR. Histamine in the eye, in Silverstein A, O'Connor G (eds). Immunology and immunopathhology of the eye. New York, Masson Publishing, 1979, pp 362-4
26. Abelson MB, Allansmith MR, Friedlander MH. Effects of topically applied ocular decongestant and antihistamine. Am J Opthalmol 1980;90:254-7
27. Abelson MB, Grant KK, Chapin MJ. Prostaglandins, in Abelson MB (ed). Allergic diseases of the eye. WB Saunders, Philadelphia, 2001, pp 103-6
28. Abelson MB, Madiwale NA, et al. The role of prostaglandin D2 in allergic ocular disease, in O'Connor GR, Chandler JW (eds). Advances in immunology and immunopathology of the eye. New York, Masson, 1985, p 163
29. George MA, Smith LM, Berdy GJ, et al Platelet activating factor-induced inflammation following topical ocular challenge (abstract). Invest Ophthalmol Vis Sci 31 Suppl:63, 1990
30. Abelson MB, Grant KK, Chapin MJ. Leukotrienes, in Abelson MB. Allergic diseases of the eye. WB Saunders, Philadelphia, 2001, pp 97-102
31. Udell IJ, Abelson MB. Animal and human ocular surface response to a topical nonimmune mast cell degranulating agent (compound 48/80). Am J Ophthalmol 1981;91:226-30
32. Irani AA, Schwartz LB. Human mast cell heterogeneity. Allergy Proc 1994;15:303-8
33. Weidner N, Austen KF. Heterogeneity of mast cells at multiple body sites. Pathol Res Pract 1993;189:156-62
34. Moller C, Bjorksten B, Nilsson G, Dreborg S. The precision of the conjunctival provocation test. Allergy 1984;39:37-41
35. Abelson MB, Loeffler O. Conjunctival allergen challenge: models in the investigation of ocular allergy. Curr Allergy Asthma Rep 2003;3:363-8
36. Abelson MB, Chambers WA, Smith LM. Conjunctival allergen challenge. A clinical approach to studying allergic conjunctivitis. Arch Ophthalmol 1990;108: 84-8
37. Monson BK, Rothman JS, Raizman MB. A comparison of the efficacy and safety of nedocromil sodium 2% ophthalmic solution and olopatadine hydrochloride ophthalmic solution 0.1% in the treatment of allergic conjunctivitis in cat sensitive individuals (abstract). Invest Ophthalmol Vis Sci 2004;45:E-abstract 4827
38. Rothman JS, Raizman MB A single dose comparison of 0.1% pemirolast potassium and 0.1% olopatadine hydrochloride sodium eye drops as prevention and treatment of ocular itching in cat sensitive individuals (abstract). Invest Ophthalmol Vis Sci 2004;45:E-abstract 4835
39. Horak F, Jager S, Berger U. Onset and duration of the effects of three antihistamines in current use - astemizole, loratadine and terfenadine forte - studied during prolonged, controlled allergen challenges in volunteers. J Int Med Res. 1992 Sep;20:422-34
40. Abelson MB, Pratt S, Mussoline JF, Townsend D. One visit randomized placebo controlled CAC model study of scanning and imaging technology for objective quantification of eyelid swelling in the allergic reaction with olopatadine and artificial tears. Clin Ther. 2003; 25: 2070-84
41. Butrus S, Greiner JV, Discepola M, Finegold I. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and nedocromil sodium 2% ophthalmic solution in the human conjunctival allergen challenge model. Clin Ther 2000;22:1462-72
42. Berdy GJ, Stoppel JO, Epstein AB. Comparison of the clinical efficacy and tolerability of olopatadine hydrochloride 0.1% ophthalmic solution and loteprednol etabonate 0.2% ophthalmic suspension in the conjunctival allergen challenge model. Clin Ther 2002 24:918-29
43. D'Arienzo PA, Granet D, Epstein AB et al. Clinical efficacy of olopatadine and epinastine in allergic conjunctivitis subjects defined by sensitivity to conjunctival allergen challenge (CAC) [abstract]. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 2677
44. Brewit L H, Sistam F. Dry eye disease: the scale of the problem. Surv Ophthalmol 2001;45:199-201
45. Calabria G, Rolando M. [Definition and classification of dry eye syndromes], in Il Film Lacrimale. Fogliazza Editore, Milan 1997, pp 163-82. Italian.
46. Grant K, Abelson MB, George MA, et al. Metaplastic changes to the lid margin epithelium - a contributing factor in dry eye syndrome. Invest Ophthalmol Vis Sci 1998;39 Suppl: S538
47. Abelson MB, Ousler GW, Nally LA, Emory TB. Dry eye syndromes: diagnosis, clinical trials and pharmaceutical treatment - improving clinical trials. Adv Exp Med Biol 2002;506(PtB):1079-86
48. Christensen MT, Cohen S, Rinehart J, et al. Clinical evaluation of an HP-guar gellable lubricant eye drop for the relief of dryness of the eye. Curr Eye Res 2004;1:55-62
49. Kunert KS, Tisdale AS, Stern ME. Analysis of topical cyclosporine treatment of patients with dry eye syndrome. Arch Ophthlamol 2000:118:1489-96
50. Restasis Package Insert 2002
51. Sall KN, Cohen SM, Christensen MT. Efficacy and compatability of an HP-guar based lubricant eye drop when used as supportive therapy with a cyclosporine-based ophthalmic emulsion: Invest Ophthalmol Vis Sci 2005;46:E-abstract 2020
52. Pratt SG, Ousler GW, Schindelar M, et al. Evaluation of a novel dry eye oral supplement for the treatment of the signs and symptoms of dry eye in the Controlled Adverse Environment (CAE) model. Invest Ophthalmol Vis Sci 2005;46:E-Abstract 2047
53. Lemp MA. Report of the national eye institute/industry workshop on clinical trials in dry eyes. CLAO J 1995;21:221-32
54. Giovanoni A, Abelson MB, Rosen S, Welch D. A controlled environment approach to the study of dry eye. Invest Ophthalmol Vis Sci 1998;39 Suppl:S537
55. Ousler GW, Abelson MB, Nally, et al. Evaluation of the time to "natural compensation" in normal and dry eye subject populations during exposure to a controlled adverse environment.Adv Exp Med Biol. 2002;506(Pt B):1057-63
56. Krenzer KL, Ousler GW 3rd, Slugg A, Nau A. A comparison of the staining characteristics of rose bengal and lissamine green in their evaluation of the clinical signs of dry eye (abstract). Invest Ophthalmol Vis Sci 2000;14 Suppl:S928
57. Abdul-Fattah AM, Bhargva HN, Korb DR, et al. Quantitative in vitro comparison of fluorescein delivery to the eye via impregnated strip and volumetric techniques (abstract). Invest Ophthalmol Vis Sci 1999:40 Suppl:S544
58. Marquardt R, Stodtmeiser R, Christ T. Modification of tear film break-up time test for increased reliability, in Holly FJ (ed). The preocular tear film in health, disease and contact lens wear. Dry Eye Institute. Lubbock, TX, 1986
59. Abelson MB, Ousler GW 3rd, Nally LA, Krenzer K. Alternative reference values for tear film break-up time in normal and dry eye populations. Cornea 2000; 19:S72
60. Bentivoglio AR, Bressman SB, Cassetta E, et al. Analysis of blink rate patterns in normal subjects. Mov Disord 1997;12:1028-34
61. Nally L, Ousler GW, Abelson MB. Ocular discomfort and tear film break up time in dry eye patients. Invest Ophthalmol Vis Sci 2000; 41 Suppl. 1436
62. Ousler GW, Wilcox KA, Gupta G, et al. An evaluation of the ocular drying effects of 2 systemic antihistamines: loratadine and cetirizine hydrochloride. Ann Allergy Asthma Immunol 2004;93:460-464
63. Ang RT, Dartt DA, Tsubota K. Dry eye after refractive surgery. Curr Opin Ophthalmol 2001;12:318-22
64. Ousler GW, Welch DL, Abelson MB. A correlation between ocular symptoms and corneal sensitivity in dry eye patients: a symptomatic zone. Invest Ophthalmol Vis Sci 2003;44:E-abstract 2484
65. Ousler GW, Emory TB, Welch D, Abelson MB. Factors that influence the interblink interval (IBI) as measured by the ocular protection index. Invest Ophthalmol Vis Sci 2002;43: E-Abstract 56
66. Ousler GW, Lemp MA, Schindelar MR, Abelson MB. Tear film break up patterns (TFBUP) - a novel method of evaluating tear film stability (abstract). The Ocular Surface 2005 3 suppl: S100